awmsg logo



ponatinib (Iclusig®)


Reference No. 1163

Publication date:
13/01/2015


Appraisal information

ponatinib (Iclusig®) 15 mg film-coated tablet
ponatinib (Iclusig®) 45 mg film-coated tablet


Company: ARIAD Pharma UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 15/10/2014
AWMSG meeting date: 12/11/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 3714
Ministerial ratification: 09/01/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Ponatinib (Iclusig®) is recommended as an option for use within NHS Wales for the treatment of adult patients with: • Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation; • Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download